cPrPMEDAP

Name: cPrPMEDAP
Brand: MedChemExpress
SKU: HY-101677
Rating: 4.5 (1 reviews)

Cat. No.: HY-101677 Purity: 99.62%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

cPrPMEDAP is an intermediate metabolite of GS-9219. cpr-PMEDAP functions as a proagent of the guanine nucleotide analog PMEG and has antiproliferative activity. cPrPMEDAP is negatively charged at physiologic pH and has poor permeability into the skin.

For research use only. We do not sell to patients.

cPrPMEDAP Chemical Structure

CAS No. : 182798-83-0

Size	Price	Stock	Quantity
5 mg	USD 381	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 610	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 1220	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 1960	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 3130	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
Ca-Ski	EC₅₀	1410 nM Compound: cPrPMEDAP	Antiproliferative activity against HPV-transformed human CaSki cells after 7 days by SRB assay Antiproliferative activity against HPV-transformed human CaSki cells after 7 days by SRB assay	[PMID: 19398642]
CCRF-HSB-2	CC₅₀	3 μM Compound: PME-cPrDAP	Cytotoxicity against human HSB2 cell after 4 hrs by MTS assay Cytotoxicity against human HSB2 cell after 4 hrs by MTS assay	[PMID: 18852272]
Daudi	CC₅₀	20 μM Compound: PME-cPrDAP	Cytotoxicity against human Daudi cell after 4 hrs by MTS assay Cytotoxicity against human Daudi cell after 4 hrs by MTS assay	[PMID: 18852272]
HeLa	EC₅₀	6930 nM Compound: cPrPMEDAP	Antiproliferative activity against HPV-transformed human HeLa cells after 7 days by SRB assay Antiproliferative activity against HPV-transformed human HeLa cells after 7 days by SRB assay	[PMID: 19398642]
HFF	EC₅₀	< 0.06 μM Compound: PME-cPrDAP	Antiviral activity against Murine cytomegalovirus Smith infected in HFF cells by plaque reduction assay Antiviral activity against Murine cytomegalovirus Smith infected in HFF cells by plaque reduction assay	[PMID: 18852272]
HFF	CC₅₀	> 100 μM Compound: PME-cPrDAP	Cytotoxicity against human HFF cells after 7 days by neutral red dye method Cytotoxicity against human HFF cells after 7 days by neutral red dye method	[PMID: 18852272]
HFF	EC₅₀	0.4 μM Compound: PME-cPrDAP	Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells by plaque reduction assay Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells by plaque reduction assay	[PMID: 18852272]
HFF	EC₅₀	0.8 μM Compound: PME-cPrDAP	Antiviral activity against Varicella zoster virus Ellen infected in HFF cells by plaque reduction assay Antiviral activity against Varicella zoster virus Ellen infected in HFF cells by plaque reduction assay	[PMID: 18852272]
HFF	EC₅₀	4 μM Compound: PME-cPrDAP	Antiviral activity against herpes simplex virus 1 E-377 infected in HFF cells by plaque reduction assay Antiviral activity against herpes simplex virus 1 E-377 infected in HFF cells by plaque reduction assay	[PMID: 18852272]
HFF	EC₅₀	7.9 μM Compound: PME-cPrDAP	Antiviral activity against herpes simplex virus 2 MS infected in HFF cells by plaque reduction assay Antiviral activity against herpes simplex virus 2 MS infected in HFF cells by plaque reduction assay	[PMID: 18852272]
HT-3	EC₅₀	7040 nM Compound: cPrPMEDAP	Antiproliferative activity against HPV-non-transformed human HT3 cells after 7 days by SRB assay Antiproliferative activity against HPV-non-transformed human HT3 cells after 7 days by SRB assay	[PMID: 19398642]
ME-180	EC₅₀	8320 nM Compound: cPrPMEDAP	Antiproliferative activity against HPV-transformed human ME180 cells after 7 days by SRB assay Antiproliferative activity against HPV-transformed human ME180 cells after 7 days by SRB assay	[PMID: 19398642]
MOLT-3	CC₅₀	8.5 μM Compound: PME-cPrDAP	Cytotoxicity against human MOLT3 cell after 4 hrs by MTS assay Cytotoxicity against human MOLT3 cell after 4 hrs by MTS assay	[PMID: 18852272]
SCC-4	EC₅₀	1430 nM Compound: cPrPMEDAP	Antiproliferative activity against HPV-non-transformed human SCC4 cells after 7 days by SRB assay Antiproliferative activity against HPV-non-transformed human SCC4 cells after 7 days by SRB assay	[PMID: 19398642]
SCC-9	EC₅₀	10100 nM Compound: cPrPMEDAP	Antiproliferative activity against HPV-non-transformed human SCC9 cells after 7 days by SRB assay Antiproliferative activity against HPV-non-transformed human SCC9 cells after 7 days by SRB assay	[PMID: 19398642]
SiHa	EC₅₀	> 20000 nM Compound: cPrPMEDAP	Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 72 to 75 hrs by ELISA Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 72 to 75 hrs by ELISA	[PMID: 19398642]
SiHa	EC₅₀	1500 nM Compound: cPrPMEDAP	Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 6 to 9 hrs by ELISA Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 6 to 9 hrs by ELISA	[PMID: 19398642]
SiHa	EC₅₀	1860 nM Compound: cPrPMEDAP	Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 3 to 6 hrs by ELISA Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 3 to 6 hrs by ELISA	[PMID: 19398642]
SiHa	EC₅₀	2300 nM Compound: cPrPMEDAP	Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 24 to 27 hrs by ELISA Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 24 to 27 hrs by ELISA	[PMID: 19398642]
SiHa	EC₅₀	2650 nM Compound: cPrPMEDAP	Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 48 to 51 hrs by ELISA Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 48 to 51 hrs by ELISA	[PMID: 19398642]
SiHa	EC₅₀	290 nM Compound: cPrPMEDAP	Antiproliferative activity against HPV-transformed human SiHa cells after 7 days by SRB assay Antiproliferative activity against HPV-transformed human SiHa cells after 7 days by SRB assay	[PMID: 19398642]
SiHa	EC₅₀	8840 nM Compound: cPrPMEDAP	Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 3 hrs by ELISA Inhibition of DNA synthesis in HPV-transformed human SiHa cells assessed as decrease in BrdU incorporation after 3 hrs by ELISA	[PMID: 19398642]

In Vitro

cPrPMEDAP shows antiproliferative activity in SiHa cells with an EC₅₀ of 290 nM (SiHa cells: HPV-transformed cervical carcinoma cell lines)^[1].
PMEG forms an active phosphorylated metabolite, PMEG diphosphate (PMEG-DP), in cells, which inhibits the growth of various transformed cell lines due to potent inhibition of the nuclear DNA polymerases α, δ and ɛ, resulting in inhibition of DNA synthesis and/or DNA repair. In animal models, PMEG has antiproliferative effects; the utility of PMEG as an antiproliferative agent is limited by its poor cellular permeability and toxicity. cPrPMEDAP has similar antiproliferative effects in vitro and reduced toxicity in vivo but, like PMEG, is negatively charged at physiologic pH and has poor permeability into the skin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

328.26

Formula

C₁₁H₁₇N₆O₄P

CAS No.

182798-83-0

Appearance

Solid

Color

Off-white to light yellow

SMILES

NC1=NC(NC2CC2)=C3N=CN(CCOCP(O)(O)=O)C3=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (30.46 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0464 mL	15.2318 mL	30.4637 mL
5 mM	0.6093 mL	3.0464 mL	6.0927 mL
10 mM	0.3046 mL	1.5232 mL	3.0464 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.62%

Select Batch:

Data Sheet (272 KB) SDS (251 KB)

COA (248 KB) HNMR (118 KB) RP-HPLC (160 KB) LCMS (223 KB)

Handling Instructions (2659 KB)

References

[1]. Compton ML, et al. 9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cpr-PMEDAP) as a prodrug of 9-(2-phosphonylmethoxyethyl)guanine (PMEG). Biochem Pharmacol. 1999;58(4):709-714. [Content Brief]

[2]. Wolfgang GH, et al. GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions. Antimicrob Agents Chemother. 2009;53(7):2777-2784. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.0464 mL	15.2318 mL	30.4637 mL	76.1591 mL
	5 mM	0.6093 mL	3.0464 mL	6.0927 mL	15.2318 mL
	10 mM	0.3046 mL	1.5232 mL	3.0464 mL	7.6159 mL
	15 mM	0.2031 mL	1.0155 mL	2.0309 mL	5.0773 mL
	20 mM	0.1523 mL	0.7616 mL	1.5232 mL	3.8080 mL
	25 mM	0.1219 mL	0.6093 mL	1.2185 mL	3.0464 mL
	30 mM	0.1015 mL	0.5077 mL	1.0155 mL	2.5386 mL

cPrPMEDAP Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

cPrPMEDAP182798-83-0Drug Metaboliteprodrugnucleotide analogantiproliferativeSiHa cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

cPrPMEDAP

Customer Review

cPrPMEDAP Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

cPrPMEDAP Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

cPrPMEDAP Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report